Skip to main content
Healthcare

Healthcare Global Exposure: International Markets and Currency Risk

Pomegra Learn

How Does International Exposure Affect Healthcare Investment?

Major US healthcare companies generate substantial portions of their revenue outside the United States — large pharmaceutical companies typically derive 40–60% of revenue internationally, and medical device companies have similar or higher international exposure. This global footprint creates opportunities (access to growing international markets) and risks (currency translation effects, international pricing regulations that are more restrictive than the US, emerging market access complexity). Understanding the international dimensions of healthcare sector investing helps investors evaluate earnings quality, currency headwind sensitivity, and market growth opportunities that differ substantially from the US market.

Quick definition: Healthcare global exposure varies significantly by subsector: large pharmaceutical companies (Pfizer, Merck, Johnson & Johnson) derive 40–60% of revenue internationally; medical device companies have similar international exposure; managed care companies are primarily US-domestic; and biotech companies vary from US-focused to globally distributed depending on product approval geographies.

Key takeaways​

  • Large pharmaceutical companies typically derive 40–60% of revenue from outside the US — creating meaningful currency translation exposure when the US dollar strengthens against the euro, Japanese yen, and emerging market currencies
  • European drug pricing operates through national health technology assessments (HTA), reference pricing, and parallel import regulations that result in significantly lower prices than the US — often 50–80% below US list prices for the same drugs
  • Emerging markets (China, India, Brazil) represent growing pharmaceutical markets with expanding middle classes and improving healthcare infrastructure — but generic drug dominance, government procurement, and regulatory barriers limit branded drug access
  • Novo Nordisk (Danish), AstraZeneca (British-Swedish), Roche (Swiss), Sanofi (French), and Novartis (Swiss) are major European pharmaceutical companies with significant US-listed ADR or US-traded shares — providing international healthcare exposure
  • Japan's pharmaceutical market is the world's third largest — with PMDA approval requirements, NHI drug price listings, and biennial drug price cuts creating a distinct regulatory and pricing environment

US pharmaceutical pricing versus international markets​

The US pricing premium: The United States represents approximately 40–50% of global pharmaceutical revenue despite being approximately 4–5% of the global population — reflecting the unique US pricing environment where manufacturers have significant pricing freedom relative to government price-controlled international markets. This US pricing premium is a primary driver of pharmaceutical company profitability and R&D investment economics.

European reference pricing and HTA: European countries use Health Technology Assessment (HTA) to evaluate the clinical value of new drugs and negotiate prices with manufacturers based on comparative effectiveness. Germany's AMNOG (2011) system evaluates new drugs against best available therapy and sets prices accordingly — drugs with minimal additional benefit may receive no premium over generic alternatives. France, Italy, Spain, and the UK operate similar systems.

Reference pricing cascades: Several countries tie their national drug prices to the prices paid in other countries — International Reference Pricing (IRP). When a manufacturer accepts a low price in one country to achieve access, that price can become the reference for other countries' negotiations. This dynamic creates strategic pricing challenges: manufacturers must balance access objectives (reaching patients in lower-income countries) against IRP risk from those lower prices spreading to wealthier markets.

Parallel imports within the EU: Within the European Union, parallel importers can legally purchase drugs in lower-priced EU countries and resell them in higher-priced EU countries — reducing manufacturer revenue in higher-priced markets. The UK and Northern European markets have been particularly affected by parallel imports from Southern and Eastern Europe.

Currency impact on pharmaceutical earnings​

Revenue translation versus transaction exposure: Pharmaceutical companies face both revenue translation exposure (non-US revenue denominated in foreign currencies) and transaction exposure (drugs priced in local currencies but costs incurred in US dollars). When the US dollar strengthens, revenue reported in USD from European, Japanese, and emerging market operations declines even if local currency revenue is stable.

Hedging programs: Major pharmaceutical companies operate currency hedging programs — forward contracts, options, and natural hedges (matching revenue currencies with cost currencies where possible). Pfizer, Merck, and J&J all discuss their hedging programs in quarterly earnings and provide constant-currency revenue growth figures that strip out currency translation effects.

Constant-currency reporting: Pharmaceutical investors should focus on constant-currency organic growth to evaluate operational performance separately from currency effects. A pharmaceutical company reporting 5% total revenue growth but 10% constant-currency growth is actually performing well operationally — the 5% difference is currency headwind from dollar strength, not business deterioration.

Japan's yen sensitivity: Pharmaceutical revenue from Japan is significant (Japan is the world's third-largest pharmaceutical market) and is denominated in Japanese yen. Extended periods of yen weakness (as experienced during 2022–2024 with dollar-yen moving from approximately 115 to approximately 150) create meaningful negative translation effects for pharmaceutical companies with significant Japan revenue.

How it flows​

European pharmaceutical companies as investment alternatives​

Novo Nordisk (Denmark): Novo Nordisk is now among the world's most valuable pharmaceutical companies following GLP-1 drug success — with a market cap that surpassed Denmark's entire GDP. Novo Nordisk provides pure-play GLP-1 exposure as Eli Lilly's primary competitor, listed on the Copenhagen Stock Exchange and available through NYSE-listed ADRs. Danish krone and euro currency exposure provides US investors with European healthcare diversification.

Roche (Switzerland): Roche is the world's leading oncology pharmaceutical company and the largest diagnostics company — combining pharmaceutical drug discovery (Herceptin, Avastin, cancer immunotherapy) with Roche Diagnostics (laboratory analyzers, molecular diagnostics, clinical chemistry). Swiss franc denomination; available through ADRs. Roche's diagnostics business provides diversification from pure pharmaceutical risk.

AstraZeneca (UK/Sweden): AstraZeneca has transformed from a declining pharmaceutical company into one of the fastest-growing major pharmaceutical companies through a focused oncology strategy (Tagrisso, Imfinzi, Enhertu) and cardiovascular/respiratory portfolio. Listed on London Stock Exchange and NASDAQ (AZN).

Novartis and Sanofi: Novartis (Swiss) focuses on innovative pharmaceuticals and has been divesting mature generic drug assets (Sandoz spinoff) to concentrate on novel therapies. Sanofi (French) has a diverse portfolio spanning diabetes (insulin biosimilars), oncology, and immunology. Both provide European pharmaceutical exposure with CHF and EUR currency characteristics.

Emerging market healthcare opportunities​

China pharmaceutical market: China is the world's second-largest pharmaceutical market and growing rapidly — driven by an aging population, expanding middle class, and government prioritization of healthcare access. However, the market presents challenges for multinational pharmaceutical companies: domestic Chinese pharmaceutical companies are highly competitive in generics and increasingly in innovative drugs; government volume-based procurement (VBP) programs mandate large price cuts (70–95%) to participate in public hospital tenders; and regulatory requirements for local clinical trials create additional development costs.

India pharmaceutical dynamics: India's pharmaceutical market is dominated by generics — both domestic generics for Indian patients and generic manufacturing for global export. Branded pharmaceutical penetration is low; government price controls on essential medicines limit pricing. However, India's growing middle class and private health insurance expansion create premium branded drug demand in urban markets.

Latin American markets: Brazil, Mexico, and Colombia represent significant Latin American pharmaceutical markets — with public procurement systems (Sistema Único de Saúde in Brazil) that dominate healthcare delivery and create price-sensitive purchasing environments. Private insurance markets provide premium branded drug opportunities in urban middle-class segments.

Emerging market currency risk: Pharmaceutical revenue from emerging markets is subject to significant currency volatility — the Brazilian real, Argentine peso, Turkish lira, and Indian rupee have experienced substantial depreciation against the US dollar over various periods. Companies with large emerging market revenue must manage both translation risk and the risk of local currency earnings being "trapped" in jurisdictions with capital controls or repatriation restrictions.

Medical device international exposure​

Asia-Pacific procedure volume growth: Medical device companies have significant Asia-Pacific exposure — Japan, China, South Korea, and Australia represent major device markets. Procedure volume growth in Asia-Pacific markets has been faster than in the US and Europe as middle-class healthcare utilization expands toward developed-market levels. Intuitive Surgical, Medtronic, and orthopedic device companies all cite Asia-Pacific as a key growth region.

Reimbursement barriers in international markets: Medical device reimbursement requires local regulatory approval and health technology assessment in most markets — separate from US FDA clearance. European CE marking, Japan PMDA approval, and China NMPA approval represent distinct regulatory pathways with their own timelines and requirements. The time and cost of seeking international approvals delay international revenue contribution from new device launches.

China's device localization pressure: China has increasingly pressured hospital systems to procure locally manufactured medical devices rather than imported devices from US and European manufacturers. Volume-based procurement programs for high-value devices (coronary stents, orthopedic implants, cardiac rhythm management devices) have dramatically reduced prices in Chinese hospital markets, challenging multinational device company profitability in China.

International healthcare ETFs​

International healthcare exposure: US investors seeking international healthcare exposure can access European and global pharmaceutical companies through international ETFs — iShares Global Healthcare ETF (IXJ) includes both US and international healthcare companies; iShares MSCI Europe Healthcare ETF provides focused European healthcare exposure. These vehicles provide Roche, Novartis, AstraZeneca, Novo Nordisk, and Sanofi exposure alongside US companies.

Currency considerations: International healthcare ETFs expose investors to both healthcare operational performance and currency effects. Euro, Swiss franc, British pound, and Danish krone movements affect USD returns from European healthcare holdings. Hedged versions of international ETFs (which mitigate currency translation effects) are available but typically carry higher expense ratios.

Common mistakes​

Ignoring constant-currency metrics when evaluating pharmaceutical earnings quality. Pharmaceutical companies reporting total revenue growth that includes significant currency headwinds may have strong underlying operational performance obscured by dollar strength. Comparing reported revenue growth (total) to constant-currency growth reveals the currency translation effect and allows more accurate assessment of underlying business momentum.

Assuming US drug pricing is replicable internationally. US pharmaceutical company revenue models that depend on premium US pricing are not replicable in international markets. Companies that lose competitive position in the US face a much steeper earnings cliff than companies with well-developed international businesses at locally appropriate price points — because no international market can substitute for the US margin profile.

FAQ​

How much of major pharmaceutical company revenue comes from outside the US?​

Major US pharmaceutical companies vary significantly in their international revenue exposure: Merck derives approximately 40–45% of revenue internationally; Pfizer approximately 45–55%; Johnson & Johnson (pharmaceutical segment) approximately 45–55%; AbbVie approximately 35–40% (with significant EU biosimilar headwinds for Humira). Annual reports and Form 10-K geographic segment disclosures, filed with the SEC at sec.gov, provide precise revenue breakdowns by geography for each company.

Summary​

Healthcare global exposure creates both opportunity and risk across subsectors: large pharmaceutical companies derive 40–60% of revenue internationally, with European HTA pricing systems generating 50–80% price discounts relative to US prices, Japan's biennial NHI price cuts compressing profitability, and emerging market currency volatility affecting reported earnings. Currency translation effects — particularly dollar strengthening against euro and yen — create revenue and earnings headwinds that investors should separate from underlying operational performance through constant-currency analysis. European pharmaceutical companies (Novo Nordisk, Roche, AstraZeneca, Novartis) provide investment alternatives with different geographic revenue mixes and therapeutic focus areas. Emerging markets offer long-run growth potential but present generic drug dominance, government volume-based procurement price pressure, and currency risk that constrain near-term profitability for branded pharmaceutical companies.

Next​

→ Biosimilars: Generic Competition for Biologic Drugs